Navigation Links
Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical,Trial Data

any future results, performance or achievements expressed or implied by such forward-looking statements. Statements of "belief" with respect to reformulation, the undertaking of an additional clinical trial for CRD5 as well as CRD5's efficacy in raising HDL levels, are based primarily upon results derived to date from the Company's pre-clinical research and development and its results from completed Phase I and Phase I/II clinical trials. While the Company believes that it has reasonable scientific basis upon which to make such statements, it is not possible to predict whether a new therapeutic agent will be prove to be safe and/or effective in humans. The Company cannot guarantee that it actually will achieve the plans, intentions or expectations. and undue reliance should not be placed on those forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's periodic regulatory filings, which can be found in the SEDAR database at www.sedar.com.

For further information: Investor Relations Joanna Longo The Equicom Group Inc. (416) 815-0700 ext. 233 jlongo@equicomgroup.com

Media Relations Linda Forrest inmedia Public Relations (613) 234-7227 ext. 234 lforrest@inmedia.com


'"/>




Page: 1 2 3

Related medicine technology :

1. Liponex Inc. Reports Phase I/II Clinical Trial Data for CRD5
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Liponex Inc Reports Further Analysis CRD5 Phase Clinical Trial Data
(Date:1/15/2014)... Corporation (the "Company") (NASDAQ: CLSN ) today ... to purchase an aggregate of approximately $15 million of ... offering, led by a dedicated health care fund. ... these investors pursuant to which the Company agreed to ...
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:4/23/2014)... journal Oncotarget , explored tumour heterogeneity ... own DNA signatures within the same cancer. Such ... targeted treatment strategies. , Firstly they confirmed the ... the KRAS or BRAF mutation. Secondly, they found ... mutation have that specific mutation present uniformly throughout ...
(Date:4/23/2014)... has been a rapidly evolving pursuit with many ... in the research road, scientists have found a ... with the disease. The report, which appears in ... have important implications for developing novel treatments. , ... that for years, research has suggested a link ...
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern ... suffering from depression . , A team ... mechanism by which ghrelin (a hormone with natural anti-depressant ... a potentially powerful new treatment for depression in the ... , The study, published online in April,s issue ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2
... pill that will help protect and even treat hearing loss from ... say it has picked up steam in just the past few ... Marines will face rifle training with not only foam plugs in ... herbal tea. ,They'll take it with every meal during their ...
... observational studies previously conducted in elderly populations have ... performed before intracoronary stents and use of glycoprotein ... Hanoch Hod, of Chaim Sheba Medical //Center in ... patients aged 70 or older treated for ST-elevation ...
... new studies have identified genetic activity that appears to ... alters a person's perceptions of reality, emotions and thought ... of the world's population, typically surface during the late ... Rockefeller, University in New York and colleagues identified two ...
... vasectomy, contraception is typically left up to the woman. ... in a woman's contraceptive repertoire. Until now, men have ... searching for new options. Now, they may have one.// ... 12 percent. Vasectomies are considered permanent. Dr. Wang, of ...
... periods ,Seasonale, a new drug approved by the Food ... women's periods to four a year by taking the hormones ... spans of time.// ,Seasonale would be another alternative ... prevention of pregnancy and are comfortable taking a hormonal contraceptive, ...
... for some doctors who think it's time to replace the ... invented it in the early 1800s. "The stethoscope is based ... to distinguish between a heart that is beating well, and ... heart muscle is very weakened, but unless that weakening leads ...
Cached Medicine News:Health News:Pill might be able to reduce the damage loud noise does to your hearing 2Health News:Pill might be able to reduce the damage loud noise does to your hearing 3Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Gene Activity connected to Schizophrenia 2Health News:New birth control to limit women's periods 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: